Research ArticleOriginal Article
Open Access

Endocrinopathies complicating transfusion-dependent hemoglobinopathy

Abdulmoein E. Al-Agha, Noor S. Bawahab, Sarah A. Nagadi, Shaimaa A. Alghamdi, Dalia A. Felemban and Asmaa A. Milyani
Saudi Medical Journal February 2020, 41 (2) 138-143; DOI: https://doi.org/10.15537/smj.2020.2.24845

References

  1. ↵
    1. Deborah Rund,
    2. Eliezer Rachmilewitz M
    (2005) Mb -Thalassemia. N Engl J Med 353:1135–1146.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Gamberini MR,
    2. Fortini M,
    3. De Sanctis V,
    4. Gilli G,
    5. Testa MR
    (2004) Diabetes mellitus and impaired glucose tolerance in thalassemia major:Incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev 2:285–291.
    OpenUrlPubMed
  3. ↵
    1. De Sanctis V,
    2. Elsedfy H,
    3. Soliman AT,
    4. Elhakim IZ,
    5. Soliman NA,
    6. Elalaily R,
    7. et al.
    (2016) Endocrine profile of ?-thalassemia major patients followed from childhood to advanced adulthood in a tertiary care center. Indian J Endocrinol Metab 4:451–459.
    OpenUrl
  4. ↵
    1. Malik S,
    2. Syed S,
    3. Ahmed N
    (2009) Complications in transfusion-dependent patients of ?-thalassemia major. PakJ Med Sci 25:678–682.
    OpenUrl
  5. ↵
    1. Neufeld EJ
    (2006) Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major:New data, new questions. Blood 107:3436–3441.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Chatterjee R,
    2. Bajoria R
    (2009) New concept in natural history and management of diabetes mellitus in thalassemia major diabetes and thalassemia. Hemoglobin 33:127–130.
    OpenUrl
  7. ↵
    1. Cappellini MD,
    2. Cohen A,
    3. Eleftheriou A,
    4. Piga A,
    5. Porter J,
    6. Taher A
    (2008) Guidelines for the Clinical Management of Thalassemia (Thalassemia International Federation, Nicosia (CY)), 2nd ed.
  8. ↵
    1. Moayeri H,
    2. Oloomi Z
    (2006) Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major. Arch Iran Med 9:329–334.
    OpenUrlPubMed
  9. ↵
    1. Landau H,
    2. Matoth I,
    3. Landau-Cordova Z,
    4. Goldfarb A,
    5. Rachmilewitz EA,
    6. Glaser B
    (1993) Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassemia major. Clin Endocrinol (Oxf) 38:55–61.
    OpenUrlPubMed
  10. ↵
    1. Joshi R,
    2. Phatarpekar A
    (2013) Endocrine abnormalities in children with beta thalassemia major. Sri Lanka J. Child Health 42:81–86.
    OpenUrl
  11. ↵
    1. Cario H,
    2. Holl RW,
    3. Debatin KM,
    4. Kohne E
    (2003) Insulin sensitivity and ?-cell secretion in Thalassemia major with secondary hemochromatosis:Assessment by oral glucose tolerance test. Eur J Pediatr 162:139–146.
    OpenUrlPubMedWeb of Science
  12. ↵
    1. de Assis RA,
    2. Ribeiro AA,
    3. Kay FU,
    4. Rosemberg LA,
    5. Nomura CH,
    6. Loggetto SR,
    7. et al.
    (2012) Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients. Eur J Radiol 81:1465–1470.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Mahachoklertwattana P,
    2. Sirikulchayanonta V,
    3. Chuansumrit A,
    4. Karnsombat P,
    5. Choubtum L,
    6. Sriphrapradang A,
    7. et al.
    (2003) Bone histomorphometry in children and adolescents with ?-thalassemia disease:Iron-associated focal osteomalacia. J Clin Endocrinol Metab 88:3966–3972.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Bordbar M,
    2. Bozorgi H,
    3. Saki F,
    4. Haghpanah S,
    5. Karimi M,
    6. Bazrafshan A,
    7. et al.
    (2019) Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients:a historical cohort study in Southern Iran. J Endocrinol Invest 42:1467–1476.
    OpenUrl
  15. ↵
    1. Dhouib NG,
    2. Khaled M,
    3. Ouederni M Ben,
    4. Besbes H,
    5. Kouki R,
    6. Mellouli F,
    7. et al.
    (2018) Growth and endocrine function in Tunisian thalassemia major patients. Mediterr J Hematol Infect Dis 10:e2018031.
    OpenUrl
  16. ↵
    1. De Sanctis V,
    2. Elsedfy H,
    3. Soliman AT,
    4. Elhakim IZ,
    5. Kattamis C,
    6. Soliman NA,
    7. et al.
    (2016) Clinical and biochemical data of adult thalassemia major patients (TM) with multiple endocrine complications (MEC) versus TM patients with normal endocrine functions:A long-term retrospective study (40 years) in a tertiary care center in Italy. Mediterr J Hematol Infect Dis 8:e2016022.
    OpenUrl
  17. ↵
    1. Bazi A,
    2. Harati H,
    3. Khosravi-Bonjar A,
    4. Rakhshani E,
    5. Delaramnasab M
    (2018) Hypothyroidism and hypoparathyroidism in thalassemia major patients:A study in Sistan and Baluchestan Province, Iran. Int J Endocrinol Metab 16:e13228.
    OpenUrl
  18. ↵
    1. Belhoul KM,
    2. Bakir ML,
    3. Saned MS,
    4. Kadhim AMA,
    5. Musallam KM,
    6. Taher AT
    (2012) Serum ferritin levels and endocrinopathy in medically treated patients with ? thalassemia major. Ann Hematol 91:1107–1114.
    OpenUrlPubMed
  19. ↵
    1. Isik P,
    2. Yarali N,
    3. Tavil B,
    4. Demirel F,
    5. Karacam GB,
    6. Sac RU,
    7. et al.
    (2014) Endocrinopathies in Turkish children with beta thalassemia major:Results from a single center study. Pediatr Hematol Oncol 31:607–615.
    OpenUrl
  20. ↵
    1. De Sanctis V,
    2. Eleftheriou A,
    3. Malaventura C
    (2004) Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassemia. Prevalence of endocrine complications and short stature in patients with Thalassemia major:A multicenter study by the Thalassemia International Federation (TIF). Pediatr Endocrinol Rev 2:249–255.
    OpenUrlPubMed
  21. ↵
    1. Shamshirsaz AA,
    2. Bekheirnia MR,
    3. Kamgar M,
    4. Pourzahedgilani N,
    5. Bouzari N,
    6. Habibzadeh M,
    7. et al.
    (2003) Metabolic and endocrinologic complications in beta-thalassemia major:A multicenter study in Tehran. BMC Endocr Disord 3:4.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Vogiatzi MG,
    2. MacKlin EA,
    3. Trachtenberg FL,
    4. Fung EB,
    5. Cheung AM,
    6. Vichinsky E,
    7. et al.
    (2009) Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassemia syndromes in North America. Br J Haematol 146:546–556.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Soliman A,
    2. Adel A,
    3. Wagdy M,
    4. Al Ali M,
    5. ElMulla N
    (2008) Calcium homeostasis in 40 adolescents with beta-thalassemia major:A case-control study of the effects of intramuscular injection of a megadose of cholecalciferol. Pediatr Endocrinol Rev 6:149–154.
    OpenUrlPubMed
  24. ↵
    1. Mohammadian S,
    2. Bazrafshan HR,
    3. Sadeghi-Nejad A
    (2003) Endocrine gland abnormalities in thalassemia major:a brief review. J Pediatr Endocrinol Metab 16:957–964.
    OpenUrlPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords